单克隆抗体治疗小鼠宫颈癌  

Monoclonal Antibody Therapy of Mouse Uterine Cervical Carcinoma

作　　者：邬淑云[1] 温淦昇 张华[1] 张纪宁 黎曰真[1] 

机构地区：[1]江西医学院肿瘤免疫研究室

出　　处：《单克隆抗体通讯》1994年第1期12-17,共6页

摘　　要：本文探讨小鼠宫颈癌单克隆抗体（ＡＴ１４－１）对带瘤动物的疗效。动物经不同途径接种不同数量的可移植性宫颈癌（Ｕ１４）细胞；然后给治疗组的动物从腹腔注入不同剂量的ＡＵ１４－１。结果表明，ＡＵ１４－１可延长带有腹水型或实体型肿瘤小鼠的存活期，且可治愈其中某些动物；但其功效受不列条件的制约：接种的肿瘤细胞数量，治疗的肿瘤类型，所用的单克隆抗体剂量，以及单克隆抗体与肿瘤细胞的结合程度。本研究提示，ＡＵ１４－１在特定条件下有可能应用于人体宫颈癌的免疫治疗。in the present report,therapeutic efficacy of monoclonal alntibody (AU14-1)against mouse uterine cervical carcinoma(U14)on animals bearing tumors has been evaluated.Animals were respectively implanted with different number of transplantable U14 cells and in various ways,and then different doses of AU14-1 were injected into the peritoneal cavities of the animals in test groups.The resul is showed that AU14-1prolonged survival time of mice bearing the ascites or solid form of transplanted U14,and even resulted in the cure of some animals bearing tumors;but therapeutic effects of antibody were limitod by the following conditions:the number of tumor cells implanted,the type of tumors,the dose of AU14-1 used and the degree of binding AU14-1to tumor cell surface.This study suggests that AU14-1 may be used for immunotherapy of human uterine cervical carcinoma under special conditions.

关 键 词：单克隆抗体 宫颈癌 肿瘤 免疫疗法 

分 类 号：R737.330.5[医药卫生—肿瘤]